FDA approval of Biogen’s Aducanumab could change the Alzheimer’s treatment landscape

Aducanumab is a recombinant human mAb that binds primarily to aggregated forms of Aβ, including soluble oligomers and insoluble fibrils. Credit: Shutterstock + PopTika



  • Biogen Aducanumab